Aytu BioPharma (NASDAQ:AYTU) Stock Rating Upgraded by Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research analysts have also weighed in on AYTU. Wall Street Zen raised shares of Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Aytu BioPharma presently has an average rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Stock Down 5.7%

Aytu BioPharma stock opened at $2.30 on Monday. Aytu BioPharma has a 1-year low of $1.26 and a 1-year high of $3.07. The firm has a market capitalization of $24.68 million, a price-to-earnings ratio of -0.60 and a beta of 0.28. The firm’s fifty day moving average price is $2.59 and its two-hundred day moving average price is $2.44. The company has a current ratio of 1.16, a quick ratio of 1.03 and a debt-to-equity ratio of 0.70.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in shares of Aytu BioPharma by 23.3% in the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after purchasing an additional 8,222 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Aytu BioPharma in the fourth quarter valued at about $67,000. Diadema Partners LP raised its holdings in shares of Aytu BioPharma by 12.1% in the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after purchasing an additional 33,118 shares during the last quarter. Persistent Asset Partners Ltd raised its holdings in shares of Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares during the last quarter. Finally, Rothschild Wealth LLC purchased a new stake in shares of Aytu BioPharma in the fourth quarter valued at about $52,000. 33.49% of the stock is owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.